Vorwort
Oncol Res Treat 2021;44(suppl 1):1 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 16, 2021 Category: Cancer & Oncology Source Type: research
ASCO Annual Meeting 2021: Neues zu PARP-, PD-1- und CDK4/6-Inhibitoren zur Therapie des Mammakarzinoms
Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 8, 2021 Category: Cancer & Oncology Source Type: research
A Taxonomy for Psycho-Oncological Intervention Techniques in an Acute Care Hospital in Germany
Conclusion: We developed a comprehensive and structured taxonomy of psycho-oncological intervention techniques in an acute care hospital that provides a standardized basis for systematic research and applied care. We expect our work to be continuously subjected to further development: future research should evaluate and expand our taxonomy to other contexts and care settings.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 8, 2021 Category: Cancer & Oncology Source Type: research
Adjuvant Therapy in Resected Nonmetastatic Stage II –IV Gallbladder Cancer: A Generalized Propensity Score Analysis
Conclusion: Patients with stage II GBC may not benefit from adjuvant therapy, while patients with stage III –IV GBC were shown to benefit from chemotherapy and chemoradiotherapy. Furthermore, chemoradiotherapy exhibited a superior OS. Nevertheless, the results need to be explained in the context of retrospective studies.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 2, 2021 Category: Cancer & Oncology Source Type: research
[ < sup > 18 < /sup > F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors
Conclusion: Elevated TLG on early FDG-PET seems to be associated with long-term treatment failure and a poor outcome in patients undergoing CDK4/6 inhibitor therapy for metastatic breast cancer. Early findings indicate a potential prognostic value of early FDG-PET in this setting and warrant a prospective evaluation.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - June 8, 2021 Category: Cancer & Oncology Source Type: research
MLH1 Exon 12 Gene Deletion Leading to Lynch Syndrome: A Case Report
Conclusion: Nonsense mutations and frameshift mutations of MMR genes are the most common causes of LS. Common mutations include those in MSH2, MLH1, MSH6, and PMS2. We report a mutation of MLH1 that has never been reported before. We recommend that patients with a history of colon or rectal cancer receive universal MMR or MSI testing and checkpoint inhibitor therapy for the first-line treatment of deficient MMR CRC.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - June 4, 2021 Category: Cancer & Oncology Source Type: research
Society Bulletins
Oncol Res Treat 2021;44:368 –374 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - May 28, 2021 Category: Cancer & Oncology Source Type: research
---
Oncol Res Treat 2021;44:368 –374 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - May 28, 2021 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2021;44:364 –367 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - May 28, 2021 Category: Cancer & Oncology Source Type: research
Cabozantinib plus Nivolumab: Neuer RCC-Erstlinienstandard?
Oncol Res Treat 2021;44:362 –363 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - May 28, 2021 Category: Cancer & Oncology Source Type: research
Luspatercept bei Niedrigrisiko-MDS: MEDALIST-Studie zeigt Mehrfachansprechen
Oncol Res Treat 2021;44:360 –361 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - May 28, 2021 Category: Cancer & Oncology Source Type: research
The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety
Conclusions: Platinum-containing chemotherapy remains a highly recommended therapeutic regimen due to greater effectiveness and tolerance for patients with advanced TNBC.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - May 11, 2021 Category: Cancer & Oncology Source Type: research
Society Bulletins
Oncol Res Treat 2021;44:294 –300 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - May 5, 2021 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2021;44:289 –293 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - May 5, 2021 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2021;44:286 –288 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - May 5, 2021 Category: Cancer & Oncology Source Type: research
